Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies

Padcev Plus Keytruda To Become Bladder Cancer Blockbuster

 
• By Andrew McConaghie

Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.

Seagen
Adcetris and Padcev will be the company's two main growth drivers this year. • Source: Shutterstock

More from Earnings

More from Business